Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:06
10/13/16
10/13
07:06
10/13/16
07:06

Ocular Therapeutix outlines strategy for sustained release intravitreal depots

Ocular Therapeutix (OCUL) provided an update on the company's development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small and large molecule pharmaceuticals, such as tyrosine kinase inhibitors and protein-based anti-vascular endothelial growth factors respectively, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular tissues. The goal of the company's intravitreal depot dual development program is to reduce the frequency of injections that are currently the standard of care for the treatment of wet AMD, DME and other retinal diseases. Accordingly, Ocular Therapeutix also announced today that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (REGN) for the development of a sustained release formulation of Regeneron's VEGF trap, aflibercept, for the treatment of wet age-related macular degeneration and other serious retinal diseases. Regeneron's aflibercept is currently approved by the U.S. FDA for certain indications under the brand name EYLEA. Per the agreement, Ocular Therapeutix retains all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

VDNRF

Vedanta Resources

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Downgrade
Vedanta Resources rating change  »

Vedanta Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$134.14

2.16 (1.64%)

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Options
Notable pre-earnings option play in Expedia »

Notable pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

10:40
04/25/17
04/25
10:40
04/25/17
10:40
General news
Treasury Option Action: a round of positioning »

Treasury Option Action: a…

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:39
04/25/17
04/25
10:39
04/25/17
10:39
Hot Stocks
JetBlue says fleet review 'going to take a little bit of time' »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

, SSNLF

Samsung

10:38
04/25/17
04/25
10:38
04/25/17
10:38
Periodicals
Samsung to give new MRAM memory details next month, Patently Apple says »

Following on a report…

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

SSNLF

Samsung

IBM

IBM

$161.45

0.7 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

AVXS

AveXis

$79.18

2.42 (3.15%)

10:37
04/25/17
04/25
10:37
04/25/17
10:37
Hot Stocks
AveXis says AVXS-101 appears to have favorable safety profile in Phase 1 trial »

AveXis presented results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TSLA

Tesla

$308.03

2.43 (0.80%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Periodicals
Union workers claim Tesla illegally intimidated them, BuzzFeed says »

The United Automobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

AEP

American Electric

$67.86

-0.11 (-0.16%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Hot Stocks
American Electric says to invest $17.3B in capital over next three years »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

10:35
04/25/17
04/25
10:35
04/25/17
10:35
General news
U.S. consumer confidence fell to a still-robust 120.3 »

U.S. consumer confidence…

FCX

Freeport McMoRan

$13.19

0.955 (7.81%)

10:34
04/25/17
04/25
10:34
04/25/17
10:34
Hot Stocks
Freeport McMoRan says near-term debt situation ins manageable »

At some point looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Hot Stocks
JetBlue says early A321NEOs have Pratt & Whitney GTF engines »

JetBlue says "We…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

UTX

United Technologies

$117.06

0.74 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

BIIB

Biogen

$276.86

3.92 (1.44%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Recommendations
Biogen analyst commentary  »

With Spinraza 'just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

UNXL

Uni-Pixel

$0.80

-0.01 (-1.23%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Options
Uni Pixel with higher call volume »

Uni Pixel with higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

10:30
04/25/17
04/25
10:30
04/25/17
10:30
General news
The 5.8% March U.S. new home sales surge »

The 5.8% March U.S. new…

EAT

Brinker

$43.93

-1.53 (-3.37%)

10:29
04/25/17
04/25
10:29
04/25/17
10:29
Hot Stocks
Brinker says 'comfortable' with guidance provided for FY17 »

Management said on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

JBLU

JetBlue

$21.75

0.22 (1.02%)

10:28
04/25/17
04/25
10:28
04/25/17
10:28
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on JetBlue, Embraer »

JetBlue says timing…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

QQQ

PowerShares QQQ Trust

$134.16

1.6 (1.21%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Technical Analysis
PowerShares QQQ Trust hits fresh 52-week highs »

The breakout that began…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

C

Citi

$60.29

0.85 (1.43%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Citi confirms receipt of CMA license in Saudi Arabia »

The Saudi Arabian Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

  • 25

    Jul

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
JetBlue aiming for CASM ex-fuel flat to up 1% for 2018-2020 »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BBRY

BlackBerry

$9.29

0.21 (2.31%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$81.41

-2.01 (-2.41%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Eli Lilly says hasn't contemplated scenario to not pursue baricitinib in RA »

On Eli Lilly's Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

10:25
04/25/17
04/25
10:25
04/25/17
10:25
General news
U.S. Richmond Fed manufacturing index dipped to 20 in April »

U.S. Richmond Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.